Novo Nordisk's Q2 earnings report fell short of expectations, but sales of its weight-loss drug Wegovy were impressive!
However, due to competition and slowing GLP-1 growth, the company lowered its full-year guidance and is considering a CEO change.
#NovoNordisk #NVO #StockMarket #Finance #Wegovy #Ozempic #EarningsReport
However, due to competition and slowing GLP-1 growth, the company lowered its full-year guidance and is considering a CEO change.
#NovoNordisk #NVO #StockMarket #Finance #Wegovy #Ozempic #EarningsReport
Novo Nordisk's Q2 earnings report fell short of expectations, but sales of its weight-loss drug Wegovy were impressive! 🟢
However, due to competition and slowing GLP-1 growth, the company lowered its full-year guidance and is considering a CEO change. 📉
#NovoNordisk #NVO #StockMarket #Finance #Wegovy #Ozempic #EarningsReport
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)